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Introduction. Vitamin D deficiency is associated with the onset and progression of hypertension and cardiovascular disease (CVD).
However, mechanisms underlying vitamin D deficiency-mediated increased risk of CVD remain unknown. We sought to examine
the differential effect of high-dose versus low-dose vitaminD supplementation onmarkers of arterial stiffness among∼40 vitaminD
deficient adults with prehypertension.Methods. Participants were randomized to high-dose (4000 IU/d) versus low-dose (400 IU/d)
oral vitamin D3 for 6 months. 24 hr ambulatory blood pressure (BP), carotid-femoral pulse wave velocity, and pulse wave analyses
were obtained at baseline and after 6 months of vitamin D supplementation. Results. There were no changes in resting BP or pulse
wave velocity over 6mo regardless of vitamin D dose (all 𝑝 > 0.202). High-dose vitamin D decreased augmentation index and
pressure by 12.3 ± 5.3% (𝑝 = 0.047) and 4.0 ± 1.5mmHg (𝑝 = 0.02), respectively. However, these decreases in arterial stiffness
were not associated with increases in serum 25-hydroxyvitamin D over 6mo (𝑝 = 0.425). Conclusion. High-dose vitamin D
supplementation appears to lower surrogate measures of arterial stiffness but not indices of central pulse wave velocity. Clinical
Trial Registration. This trial is registered with www.clinicaltrials.gov (Unique Identifier: NCT01240512).
1. Introduction
Vitamin D deficiency is a major public health problem,
affecting 33–58% of the US population [1, 2]. Low vitamin
D status is associated with a myriad of negative health out-
comes including poormusculoskeletal health [3, 4], cognitive
decline [5], and cancer progression andmortality [6].Ofmost
recent interest is the association between vitamin D defi-
ciency and major cardiovascular disease (CVD) risk factors,
including hypertension [4, 7–9]. Indeed a meta-analysis of
observational studies has shown that decreases in vitamin
D by 16 ng/dL confer a 16% greater risk for hypertension
[10]. Mechanisms underlying vitamin D deficiency-mediated
increased risk of hypertension are not clear but may be
related to arterial stiffness, a well-documented independent
predictor of incident hypertension [11], CVD related events
[12], and all-cause mortality [13, 14]. Interestingly, vitamin
D receptors are expressed throughout the cardiovascular
system, including endothelium and vascular smooth muscle
cells [15, 16]. Therefore, it is possible that underlying changes
in arterial stiffnessmay partially explain the reported associa-
tions among vitamin D status, blood pressure (BP), and CVD
risk.
To date, though, clinical trials investigating the relation-
ship between Vitamin D supplementation, BP, and/or arterial
stiffness have been equivocal. For example, some trials have
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reported systolic BP (SBP) reductions ranging from ∼5 to
13mmHg [17–19], while others have shown no significant
effect [20, 21]. These inconsistencies could be attributable
to heterogeneity in vitamin D dosage, initial BP status, BP
assessment, and study duration and quality. Similarly, the
few trials looking at vitamin D, BP, and arterial stiffness
have also been inconclusive, showing either a beneficial
effect or lack of effect. Since such studies to date have
been conducted in individuals on antihypertensive therapy
and without vitamin D deficiency, the clinical interpretation
of these results is questionable as the beneficial effects of
vitamin D on cardiovascular outcomes may be observed
independently or in combination with alterations to BP
[19].
Therefore, the purpose of the current analysis was to
examine the influence of high-dose and/or low-dose vitamin
D supplementation on BP as well as indices of arterial
stiffness.We hypothesized that normalization of vitaminD as
a result of supplementationwould yield significant reductions
in arterial stiffness in a dose response manner.
2. Methods
The present study is part of a larger clinical trial, “Vitamin D
Therapy in Individuals with Prehypertension or Hypertension:
TheDAYLIGHTTrial,” of which themethods have previously
been published in detail (NCT01240512) [21]. DAYLIGHT
is the largest prospective, double-blind, randomized, and
controlled trial study designed to examine the influence of
vitamin D on BP [21]. Briefly, 534 individuals (36 ± 10 yr)
with untreated, elevated BP (131 ± 10mmHg) and vitamin
D deficiency (15 ± 6.3 ng/mL) were randomized to 6 months
of low-dose (400 IU/d) or high-dose (4000 IU/d) vitamin D.
The primary endpoint of DAYLIGHT was 24 hr BP, the gold
standard of BP assessment [22]. Body Mass Index (BMI),
season, sunlight exposure, alcohol intake, and smoking status
were also collected as theymay influence the effect of vitamin
D on vascular function and BP changes from baseline.
Participants were recruited at four sites: Massachusetts Gen-
eral Hospital, Boston, MA; Cultural Wellness Center, Min-
neapolis, MN; Abbott Northwestern Hospital, Minneapolis,
MN; and Hartford Hospital, Hartford, CT. Of the four sites,
Hartford Hospital was the only site to assess arterial stiffness
before and after 6mo of vitamin D supplementation as a
secondary endpoint. The resultant substudy was performed
in 41 individuals with similar characteristics to the main
clinical trial (Table 1).
2.1. Inclusion and ExclusionCriteria. Themain study enrolled
individuals (18 to 50 yr) with clinic SBP >120mmHg and
25-hydroxyvitamin D level ≤25 ng/mL at the screening visit.
Individuals were excluded if SBP was greater than 160mmHg
and/or if DBP exceeded 99mmHg. Individuals were also
excluded if they had used any antihypertensive medication
or vitamin D supplementation (>400 IU/d) in the past 3mo
or had any known CVD.
2.2. Vitamin D Supplementation. Participants were randomly
assigned to once-daily doses of either 400 IU/d or 4000 IU/d
Table 1: Mean baseline characteristics (±SEM) of participants
randomized to high-dose versus low-dose vitamin D (𝑛 = 41).
Variable Low-dose(𝑛 = 22)
High-dose
(𝑛 = 19)
Age (years) 34.8 ± 12.8 40.4 ± 7.5∗
Male (%) 48 52
Body Mass Index (kg/m2) 30.5 ± 5.8 32.1 ± 8.7
Serum 25-hydroxyvitamin D (ng/mL) 16.5 ± 6.8 15.1 ± 5.7
Clinic SBP (mmHg) 127.8 ± 5.1 123.7 ± 4.6
Clinic DPB (mmHg) 78.6 ± 1.9 76.9 ± 3.1
Clinic heart rate (bpm) 79.3 ± 2.5 76.7 ± 3.1
24 hr mean ambulatory SBP (mmHg) 125.8 ± 9.9 126.1 ± 9.4
24 hr mean ambulatory DBP (mmHg) 77.5 ± 8.7 78.2 ± 8.0
Daytime ambulatory SBP (mmHg) 128.0 ± 10.4 128.3 ± 8.8
Daytime ambulatory DBP (mmHg) 79.6 ± 8.9 80.5 ± 7.7
Nighttime ambulatory SBP (mmHg) 114.4 ± 10.9 118.5 ± 13.2
Nighttime ambulatory DBP (mmHg) 70.0 ± 10.2 70.0 ± 11.0
Season of enrollment (%)
Winter 48 47
Spring 23 21
Summer 16 21
Fall 13 11
SBP, systolic blood pressure; DBP, diastolic blood pressure; ∗𝑝 < 0.05; high-
dose versus low-dose.
oral vitamin D (cholecalciferol; Ddrops Co., Woodbridge,
ON, Canada).
2.3. Blood Pressure Assessment. Clinic BP was assessed at
the screening visit and at each office visit using a validated
digital BP monitor (HEM-907X, Omron Healthcare, Inc.,
Bannockburn, IL) and according to standards set by the
American Heart Association (AHA) [23]. 24 hr ambulatory
BP was assessed at baseline and after 6 months (Spacelabs
Healthcare, Issaquah, WA) with an appropriately sized cuff.
Changes in clinic BP, mean 24 hr BP, and daytime and night-
time ambulatory BP were collected to explore the relation of
vitamin D status to change in clinic and 24 hr BP.
2.4. Arterial Stiffness Assessment. Measurement of arterial
stiffness parameters occurred following a 10min supine rest
period using the SphygmoCor CPV Central Blood Pres-
sure/Pulse Wave Velocity System (Sydney, Australia). Pulse
waveforms of the left carotid and left femoral artery were
recorded sequentially by applanation tonometry to deter-
mine central pulse wave velocity (PWV). Pulse waveforms
obtained over a 10 sec period at the left radial artery were used
to determine indices of pulse wave analyses (PWA), subendo-
cardial viability ratio (SEVR), augmentation pressure (AP),
and augmentation index (AIx). Measures of PWV and PWA
were performed at baseline and after 6 months of vitamin D
supplementation.
2.5. Statistical Analysis. Differences in baseline character-
istics between low-dose and high-dose vitamin D groups
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Figure 1: Serum 25-hydroxyvitamin D levels (±SD) before and after
6 months of high-dose versus low-dose supplementation.
were assessed with a one-way analysis of variance (ANOVA).
Two-way repeated measures ANOVA was used to determine
differences due to vitamin D supplementation, time, and
their interaction for arterial stiffness measures and BP. Linear
regression was performed to examine the contribution of
baseline values predicted changes in arterial stiffness, control-
ling for age and sex. Data are reported as mean ± standard
error of the mean (SEM). All statistical analyses were per-
formed using the Statistical Package for the Social Sciences
(SPSS) 19.0 program for Windows (SPSS Inc., Chicago, IL)
with 𝑝 ≤ 0.05 considered as statistically significant.
3. Results
Baseline subject characteristics for the total sample (𝑛 = 41)
are described in Table 1. Baseline parameters did not differ
between groups with the exception that subjects in the high-
dose group were slightly older than subjects in the low-dose
group (Table 1; 𝑝 < 0.05). Changes in safety laboratory
measures (i.e., plasma calcium, creatinine, phosphorus, and
transaminase) did not differ between the high-dose and low-
dose vitamin D arms at 6 months.
3.1. Vitamin D Supplementation. Mean 25-hydroxyvitamin
D levels at baseline did not differ between groups (mean,
15.7 ± 6.3 ng/mL; 𝑝 ≥ 0.05), with 93% of the study sample
<20 ng/mL, thusmeeting the criteria for vitaminDdeficiency
[24]. Over the course of 6 months, subjects receiving low-
dose (400 IU) versus high-dose vitamin D supplementation
(4,000 IU) increased 25-hydroxyvitaminDby 4.4±7.2 ng/mL
and 16.0 ± 10.7 ng/mL, respectively (Figure 1; 𝑝 < 0.01). At
the end of the study, the proportions of individuals with 25-
hydroxyvitamin D <20 ng/mL were 63% and 25% in the low-
dose and high-dose groups, respectively.
3.2. Vitamin D Supplementation and Blood Pressure. Baseline
25-hydroxyvitaminDwas negatively correlated with baseline
mean 24 hr SBP (𝑝 < 0.01) and 24 hr DBP (𝑝 < 0.05). Mean
24 hr SBP at baseline did not differ between groups (Figure 2).
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Figure 2: 24 hr mean ambulatory blood pressure before and after 6
months of high-dose versus low-dose supplementation.
Similarly, mean 24 hr DBP at baseline did not differ between
groups (Figure 2). Over the course of 6 months, there was no
change inmean 24 hr BP after low-dose or high-dose vitamin
D supplementation (Figure 2; 𝑝 ≥ 0.05), consistent with the
published findings from the main study [21]. Similarly, over
the course of 6 months, there were no changes in clinic BP,
daytime ambulatory BP, or nighttime ambulatory BP (𝑝 ≥
0.05).
3.3. Indices of Arterial Stiffness. Baseline 25-hydroxyvitamin
D was negatively associated with AP, aortic SP, and aortic PP
and tended to be associated with PWV (Table 2) (𝑝 < 0.05).
Among the high-dose group, AIx decreased by 12.3 ± 5.3%
(𝑝 < 0.05), whereas there were no similar improvements in
AIx among individuals in the low-dose group (𝑝 ≥ 0.05).
However, when AIx was heart rate adjusted (75 bpm; AIx-
75), there was no significant effect among individuals in
the high-dose and low-dose groups (ps > 0.177). Among
individuals in the high-dose group, AP decreased by 4.0 ±
1.5mmHg (Figure 3; 𝑝 < 0.05), whereas there were no
similar improvements in AP among individuals in the low-
dose group (𝑝 ≥ 0.05). Decreases in AIx and AP were not
correlated with any BP parameter (i.e., clinic or mean 24 hr),
even among individuals in the high-dose group (𝑝 ≥ 0.05).
Increases in serum 25-hydroxyvitaminDwere not associated
with reductions in AIx or AP at 6 months (𝑝 ≥ 0.05). At 6
months, there were no changes from baseline in any of the
indices obtained from PWA (i.e., SEVR, aortic SBP, DBP, and
MAP) in individuals within the entire sample, high-dose or
groups (𝑝 ≥ 0.05).
4. Discussion
The purpose of the present study was to determine the influ-
ence of high-dose and low-dose vitamin D supplementation
on markers of arterial stiffness and mean 24 hr BP. Among
the total sample, there were no significant differences in
mean 24 hr BP over 6 months regardless of vitamin D group.
However, high-dose vitamin D (4,000 IU/d) significantly
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Table 2: Relationship between baseline vitamin D and baseline
indices of arterial stiffness.
Partial 𝑟 𝑝
Heart rate (bpm) .159 0.370
Ejection duration (%) .288 0.099
Augmentation pressure (mmHg) −.340 0.049
Subendocardial viability ratio (%) −.013 0.942
Aortic systolic pressure (mmHg) −.494 0.003
Aortic diastolic pressure (mmHg) −.092 0.605
Aortic mean arterial pressure (mmHg) −.300 0.084
Aortic pulse pressure (mmHg) −.575 0.000
Pulse wave velocity (m/s) −.350 0.120
Augmentation index (%) −.128 0.445
Augmentation index @HR75 (%) −.084 0.622
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Figure 3: Augmentation pressure (±SD) before and after 6 months
of high-dose vitamin D supplementation.
lowered AIx and AP over 6 months of supplementation, with
no similar improvements observed in the low-dose group.
These results suggest that the pleiotropic, beneficial effect
of vitamin D on markers of arterial stiffness may be dose-
dependent and that previous inconsistencies in the literature
regarding vitamin D and CVD outcomes may be attributable
in part to a differential treatment effect of vitamin D dosage.
Most notably, these data refute the hypothesis that arterial
stiffness moderates BP in individuals with hypertension and
vitamin D deficiency as reductions in arterial stiffness were
observed independently of any significant reductions in BP.
Observational studies have previously shown a negative
correlation between vitamin D deficiency and indices of arte-
rial stiffness (i.e., AIx, SEVR, and PWV) [25, 26]. However,
few interventional studies have been designed to concur-
rently investigate the influence of vitaminD supplementation
on arterial stiffness and BP. Our findings are in agreement
with Al Mheid et al. who observed similar improvements
in arterial stiffness and endothelial function after normal-
ization of vitamin D (≥30 ng/dL) in 42 vitamin D deficient
(<30 ng/dL) healthy adults, with corresponding pressure
changes (mean arterial pressure, MAP: −4.6 ± 2.3mmHg)
[27]. McGreevy et al. also observed significant reductions in
median PWV and AIx 8 weeks after a single intramuscular
injection of 100,000 IU vitaminD in older adults with vitamin
D deficiency (<20 ng/mL), with a corresponding increase in
SBP [28]. Conversely, Ryu et al. investigated the influence of
2,000 IU/d versus placebo in 45 patients with type II diabetes
mellitus and vitaminD deficiency (<20 ng/mL) and found no
influence of vitamin D supplementation on arterial stiffness
or BP over 24 weeks [29]. Inconsistencies in the existing
interventional literature designed to investigate vitamin D
supplementation on arterial stiffness are likely due to the
inclusion of patients with comorbidities [29] and the use of
concomitant medications known to affect arterial stiffness
and BP (i.e., antihypertensive therapy) [28, 29] as well as
variable doses and duration of vitamin D supplementation
[27]. The present study observed beneficial decreases in AIx
and AP after 6 months of high-dose vitamin D supplemen-
tation. However, these decreases occurred without paralleled
reductions inBP, suggesting that hypertension in the presence
of vitaminD deficiency is not likely notmoderated by arterial
stiffening.
The mechanisms by which vitamin D supplementation
may reduce certain indices of arterial stiffness likely involve
the Renin-Angiotensin-Aldosterone System (RAAS) [30, 31].
Activation of RAS pathways and subsequent increases in
vasoconstrictor angiotensin II (Ang II) increase arterial stiff-
ness and vascular tone [26, 32, 33]. VitaminD receptor knock-
out mice experience a marked increase in renin expression,
plasma Ang II production, and hypertension [33], while, in
adequate levels, 25-hydroxyvitamin D inhibits macrophage
stimulation [34] and suppresses endothelin-induced vascular
smooth muscle cell proliferation [35], both of which modu-
late endothelial cell function and arterial stiffness.
In the present study, high-dose, but not low-dose, vitamin
D supplementation lowered select indices of arterial stiffness
but without paralleled reductions in BP over the course of
6 months. These results indicate that arterial stiffening does
not appear to directly moderate or influence the relationship
between hypertension and vitamin D deficiency. This is
perhaps attributable to the fact that hypertension is a mul-
tifaceted pathology, as significant improvements in arterial
stiffness after high-dose vitamin D supplementation did not
appear to even partiallymitigate elevated BP.Of note, vitamin
D supplementation improved some (i.e., AP and AIx) but not
all indices of arterial stiffness. It is unclear why certain indices
may respond to vitamin D therapy while others would not.
McEniery et al. have reported markers such as AIx to more
favorably respond to treatment interventions in individuals
<50 yr of age, while individuals >50 yr of age experience
reductions in PWV [36]. Resultantly, it has been suggested
that, in individuals <50 yr of age, such as the present study
(mean age: 37.5 ± 10.9 yr), AIx should be a more relevant
marker of arterial stiffness, thus making our findings more
clinically intriguing [36]. Nevertheless, it appears as if high
levels of vitamin D supplementation (i.e., 6x higher than
theRecommendedDietaryAllowance)maymodulate certain
pathways involved in systemic arterial stiffening and warrant
further investigation [24].
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There are several limitations to the present substudy.
First, the present study consists of a post hoc analysis of
the larger DAYLIGHT trial [21] and thus was not originally
powered to examine arterial stiffness as a major outcome.
Second, we lacked key measurements of biomarkers that
could possibly explain our findings (i.e., Ang II and renin);
therefore, the proposed mechanisms are purely speculative.
Furthermore, it is possible that the study definition of
vitamin D deficiency (≤25 ng/nL) was too high to discern a
noticeable effect of vitamin D supplementation on changes
in BP or arterial stiffness. However, the overall sample
baseline serum 25-dehydroxyvitamin D average was quite
low (15.7 ± 6.3 ng/mL), with 93% of the study sample being
<20 ng/mL. Even among individuals with large increases in
25-hydroxyvitamin D during supplementation, there was
no discernible dose response trend towards lower BP or
arterial stiffness. Lastly, decreases in certain indices of arte-
rial stiffness were not related to increases in serum 25-
dehydroxyvitamin D levels; thus it is possible that any
favorable reductions in arterial stiffness were not related to
normalization of vitamin D. However, the lack of correlation
is not strong enough to rule out this potential mechanism as
measured serum 25-dehydroxyvitaminD levelsmay not fully
explain any observable actions of vitamin D downstream or
on a cellular level.
Despite few limitations, the present study possesses sev-
eral noteworthy strengths. Prior studies examining supple-
mentation with vitamin D used various doses and types
and with less rigorous assessments of CVD parameters. We
reduced variability in the arterial stiffness and BP response
by examining the effect of two daily doses of vitamin D
(400 IU/d versus 4,000 IU/d) for 6monthswith very stringent
assessments. Arterial stiffness assessments were performed
by the same researcher to reduce intertester variability. BP
assessments were performed according to AHA guidelines
in the clinic setting as well as under conditions of daily
living using the gold standard for BP assessment (i.e., 24 hr
ABPM), again by the same researcher. Finally, to the best of
our knowledge, the present study is the largest, randomized,
and controlled trial to investigate the influence of high-
dose versus low-dose vitamin D supplementation on arterial
stiffness in vitamin D deficient individuals with elevated
but untreated BP. Thus, our findings can be confidently
generalizable as our population is representative of similar
cohorts who may be prescribed vitamin D therapy but who
may not necessarily qualify for antihypertensive therapy
according to most recent guidelines [37].
Our findings are supportive of a potential cardiovascular
health benefit of high-dose vitamin D supplementation on
arterial stiffness. However, reductions in arterial stiffness
did not result in positive, corresponding reductions of BP
suggesting that changes in arterial stiffness with vitamin
D supplementation do not appear to moderate or influ-
ence BP in this cohort. Further investigation is needed
with a randomized controlled trial intentionally designed to
determine the influence of vitamin D supplementation on
arterial stiffness among men and women with hypertension
to confirm the effects we have observed. The effectiveness
of vitamin D supplementation as a monopharmacological
or polypharmacological intervention to reduce BP, arterial
stiffness, and/or CVD risk is clinically intriguing as it is cost
effective and well tolerated and may prove to benefit other
conditions.
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